Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Dermatologic 3

Conditions

Hypoxia 4Melanoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Rectal Neoplasms 1Neoplasms 1Immune System Diseases 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × pimonidazole × Clear all
NCT04658303 2025-05-08

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

University of Pittsburgh

Recruiting
20 enrolled
Dermatologic

Immune System Diseases, Melanoma

NCT06831071 2025-05-08

Evaluation of Hypoxia in Primary Melanoma

University of Pittsburgh

Recruiting
50 enrolled
Dermatologic

Melanoma

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡